PUBLICATION REGISTRY

Go to research.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för molibresib. Visa hela publikationsregistret

A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publications in the selection

35 hits

Bibliografisk träff 2024-05-01

Pharmacologic Targeting of Histone H3K27 Acetylation/BRD4-dependent Induction of ALDH1A3 for Early-phase Drug Tolerance of Gastric Cancer.

Lee J, Mashima T, Kawata N, Yamamoto N, Morino S, Inaba S, Nakamura A, Kumagai K, Wakatsuki T, Takeuchi K, Yamaguchi K, Seimiya H.

Cancer Res Commun · research support, non-u.s. gov't; research-article; journal article · DOI 10.1158/2767-9764.crc-23-0639

Bibliografisk träff 2024-04-03

BRD4 inhibitors broadly promote erastin-induced ferroptosis in different cell lines by targeting ROS and FSP1.

Fan C, Guo X, Zhang J, Zheng W, Shi C, Qin Y, Shen H, Lu Y, Fan Y, Li Y, Chen L, Mao R.

Discov Oncol · research-article; journal article · DOI 10.1007/s12672-024-00928-y

Bibliografisk träff 2024-01-01

A Phase I/II Study of GSK525762 Combined with Fulvestrant in Patients with Hormone Receptor-positive/HER2-negative Advanced or Metastatic Breast Cancer.

Cescon DW, Hilton J, Morales Murilo S, Layman RM, Pluard T, Yeo B, Park IH, Provencher L, Kim SB, Im YH, Wyce A, Krishnatry AS, Hicks K, Zhang Q, Barbash O, Khaled A, Horner T, Dhar A, Oliveira M, Sparano JA.

Clin Cancer Res · clinical trial, phase ii; research-article; clinical trial, phase i; journal article · DOI 10.1158/1078-0432.ccr-23-0133

Bibliografisk träff 2023-11-28

Retraction Note: The BET inhibitor I-BET762 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine.

Xie F, Huang M, Lin X, Liu C, Liu Z, Meng F, Wang C, Huang Q.

Sci Rep · retraction of publication; retraction notice · DOI 10.1038/s41598-023-48298-9

Bibliografisk träff 2023-02-04

Orthodontic Compression Enhances Macrophage M2 Polarization via Histone H3 Hyperacetylation.

Wang Y, Groeger S, Yong J, Ruf S.

Int J Mol Sci · research-article; journal article · DOI 10.3390/ijms24043117

Bibliografisk träff 2023-02-01

A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies.

Dawson MA, Borthakur G, Huntly BJP, Karadimitris A, Alegre A, Chaidos A, Vogl DT, Pollyea DA, Davies FE, Morgan GJ, Glass JL, Kamdar M, Mateos MV, Tovar N, Yeh P, Delgado RG, Basheer F, Marando L, Gallipoli P, Wyce A, Krishnatry AS, Barbash O, Bakirtzi E, Ferron-Brady G, Karpinich NO, McCabe MT, Foley SW, Horner T, Dhar A, Kremer BE, Dickinson M.

Clin Cancer Res · clinical trial, phase ii; research support, non-u.s. gov't; research-article; clinical trial, phase i; journal article · DOI 10.1158/1078-0432.ccr-22-1284

Bibliografisk träff 2022-09-12

Inhibition of BRD4 Promotes Pexophagy by Increasing ROS and ATM Activation.

Kim YH, Jo DS, Park NY, Bae JE, Kim JB, Lee HJ, Kim SH, Kim SH, Lee S, Son M, Park K, Jeong K, Yeom E, Cho DH.

Cells · research support, non-u.s. gov't; research-article; journal article · DOI 10.3390/cells11182839

Bibliografisk träff 2022-06-27

Inhibition of BET Family Proteins Suppresses African Swine Fever Virus Infection.

Zhao Y, Niu Q, Yang S, Yang J, Zhang Z, Geng S, Fan J, Liu Z, Guan G, Liu Z, Zhou J, Hu H, Luo J, Yin H.

Microbiol Spectr · research support, non-u.s. gov't; research-article; journal article · DOI 10.1128/spectrum.02419-21

Bibliografisk träff 2022-03-31

NMR Molecular Replacement Provides New Insights into Binding Modes to Bromodomains of BRD4 and TRIM24.

Torres F, Walser R, Kaderli J, Rossi E, Bobby R, Packer MJ, Sarda S, Walker G, Hitchin JR, Milbradt AG, Orts J.

J Med Chem · research support, non-u.s. gov't; research-article; journal article · DOI 10.1021/acs.jmedchem.1c01703

Bibliografisk träff 2022-02-17

Inhibition of BETs prevents heat shock-induced cell death via upregulating HSPs in SV40 large T antigen transfected cells.

Zhou N, Zhang Y, Lei G, Chen Y, Lin T, Liu Q, Zhao Y, Mao J, Jiang Y, Mao R.

Genes Genomics · research support, non-u.s. gov't; journal article · DOI 10.1007/s13258-022-01228-x

Bibliografisk träff 2021-11-26

Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein in testis carcinoma and other cancers: Results of a Phase I/II open-label, dose escalation study.

Cousin S, Blay JY, Garcia IB, de Bono JS, Le Tourneau C, Moreno V, Trigo J, Hann CL, Azad AA, Im SA, Cassier PA, French CA, Italiano A, Keedy VL, Plummer R, Sablin MP, Hemming ML, Ferron-Brady G, Wyce A, Khaled A, Datta A, Foley SW, McCabe MT, Wu Y, Horner T, Kremer BE, Dhar A, O'Dwyer PJ, Shapiro GI, Piha-Paul SA.

Int J Cancer · clinical trial, phase ii; research support, non-u.s. gov't; clinical trial, phase i; journal article · DOI 10.1002/ijc.33861

Bibliografisk träff 2021-10-27

Exposure-response analysis of adverse events associated with molibresib and its active metabolites in patients with solid tumors.

Krishnatry AS, Hanze E, Bergsma T, Dhar A, Prohn M, Ferron-Brady G.

CPT Pharmacometrics Syst Pharmacol · research support, non-u.s. gov't; research-article; journal article · DOI 10.1002/psp4.12724

Bibliografisk träff 2021-06-04

Population pharmacokinetic modeling of molibresib and its active metabolites in patients with solid tumors: A semimechanistic autoinduction model.

Krishnatry AS, Voelkner A, Dhar A, Prohn M, Ferron-Brady G.

CPT Pharmacometrics Syst Pharmacol · clinical trial, phase ii; research support, non-u.s. gov't; research-article; multicenter study; clinical trial, phase i; journal article · DOI 10.1002/psp4.12639

Bibliografisk träff 2021-04-20

Preparation of Methyltriazolo[1,4]benzodiazepine via Oxidative Activation of a Thiolactam for the Synthesis of BET Inhibitor Molibresib.

Erickson GA, Hatcher MA, Journet M, Kowalski JA, Lovelace TC, Pink CJ, Xie S.

J Org Chem · journal article · DOI 10.1021/acs.joc.1c00563

Bibliografisk träff 2021-04-14

Novel brd4 inhibitors with a unique scaffold exhibit antitumor effects.

Kim YH, Kim M, Kim JE, Yoo M, Lee HK, Lee CO, Yoo M, Jung KY, Kim Y, Choi SU, Park CH.

Oncol Lett · research-article; journal article · DOI 10.3892/ol.2021.12734

Bibliografisk träff 2020-12-16

BET-Inhibitor I-BET762 and PARP-Inhibitor Talazoparib Synergy in Small Cell Lung Cancer Cells.

Fiorentino FP, Marchesi I, Schröder C, Schmidt R, Yokota J, Bagella L.

Int J Mol Sci · research-article; journal article · DOI 10.3390/ijms21249595

Bibliografisk träff 2020-08-20

An Adaptive Physiologically Based Pharmacokinetic-Driven Design to Investigate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics of Molibresib (GSK525762) in Healthy Female Volunteers.

Riddell K, Patel A, Collins G, Zhou Y, Schramek D, Kremer BE, Ferron-Brady G.

J Clin Pharmacol · research support, non-u.s. gov't; research-article; randomized controlled trial; journal article · DOI 10.1002/jcph.1711

Bibliografisk träff 2019-11-06

Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors.

Piha-Paul SA, Hann CL, French CA, Cousin S, Braña I, Cassier PA, Moreno V, de Bono JS, Harward SD, Ferron-Brady G, Barbash O, Wyce A, Wu Y, Horner T, Annan M, Parr NJ, Prinjha RK, Carpenter CL, Hilton J, Hong DS, Haas NB, Markowski MC, Dhar A, O'Dwyer PJ, Shapiro GI.

JNCI Cancer Spectr · research-article; journal article · DOI 10.1093/jncics/pkz093

Bibliografisk träff 2018-06-20

A natural compound, aristoyagonine, is identified as a potent bromodomain inhibitor by mid-throughput screening.

Kim YH, Kim M, Yoo M, Kim JE, Lee HK, Heo JN, Lee CO, Yoo M, Jung KY, Yun CS, Moon SW, Chang HK, Chung CW, Pyo S, Choi SU, Park CH.

Biochem Biophys Res Commun · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bbrc.2018.06.091

Retracted publication 2018-05-25

The BET inhibitor I-BET762 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine.

Xie F, Huang M, Lin X, Liu C, Liu Z, Meng F, Wang C, Huang Q.

Sci Rep · retracted publication; research-article; journal article · DOI 10.1038/s41598-018-26496-0

Bibliografisk träff 2018-05-16

A super-enhancer maintains homeostatic expression of Regnase-1.

Yang R, Wu Y, Ming Y, Xu Y, Wang S, Shen J, Wang C, Chen X, Wang Y, Mao R, Fan Y.

Gene · journal article · DOI 10.1016/j.gene.2018.05.052

Bibliografisk träff 2018-02-23

Targeting Epigenetics to Prevent Obesity Promoted Cancers.

Berger NA, Scacheri PC.

Cancer Prev Res (Phila) · comment; editorial; research support, n.i.h., extramural · DOI 10.1158/1940-6207.capr-18-0043

Bibliografisk träff 2017-12-15

Chemoprevention of Preclinical Breast and Lung Cancer with the Bromodomain Inhibitor I-BET 762.

Zhang D, Leal AS, Carapellucci S, Zydeck K, Sporn MB, Liby KT.

Cancer Prev Res (Phila) · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1158/1940-6207.capr-17-0264

Bibliografisk träff 2017-06-10

Selective inhibition of BET proteins reduces pancreatic damage and systemic inflammation in bile acid- and fatty acid ethyl ester- but not caerulein-induced acute pancreatitis.

Huang W, Haynes AC, Mukherjee R, Wen L, Latawiec D, Tepikin AV, Criddle DN, Prinjha RK, Smithers N, Sutton R.

Pancreatology · journal article · DOI 10.1016/j.pan.2017.06.005

Bibliografisk träff 2017-02-27

Bromodomain inhibitors, JQ1 and I-BET 762, as potential therapies for pancreatic cancer.

Leal AS, Williams CR, Royce DB, Pioli PA, Sporn MB, Liby KT.

Cancer Lett · journal article · DOI 10.1016/j.canlet.2017.02.021

Bibliografisk träff 2016-12-01

[Effect of BRD4 Inhibitor GSK525762A on Proliferation and Apoptosis of SUP-B15 Cells In Vitro and Its Possible Mechanism].

Wang X, Qi N, Ma S, Yan ZL, Wu QY, Wang L, Chen C, Xu KL.

Zhongguo Shi Yan Xue Ye Xue Za Zhi · journal article · DOI 10.7534/j.issn.1009-2137.2016.06.008

Bibliografisk träff 2015-10-01

New Synthetic Routes to Triazolo-benzodiazepine Analogues: Expanding the Scope of the Bump-and-Hole Approach for Selective Bromo and Extra-Terminal (BET) Bromodomain Inhibition.

Baud MG, Lin-Shiao E, Zengerle M, Tallant C, Ciulli A.

J Med Chem · research support, non-u.s. gov't; research-article; journal article · DOI 10.1021/acs.jmedchem.5b01135

Bibliografisk träff 2015-07-01

[In vitro study of BRD4 inhibitor GSK525762A against primary adult common B-cell acute lymphoblastic leukemia cells in vitro].

Ma S, Chen C, Zhu J, Li Y, Wang X, Song X, Cao J, Xu K.

Zhonghua Xue Ye Xue Za Zhi · research-article; journal article · DOI 10.3760/cma.j.issn.0253-2727.2015.07.007

Bibliografisk träff 2014-10-01

[Effect of BRD4 inhibitor GSK525762A on proliferation and apoptosis of KU812 leukemic cells and its mechanism].

Xu J, Wang L, Song XG, Wu QY, Zhao K, Zeng LY, Han ZX, Chen C, Xu KL.

Zhongguo Shi Yan Xue Ye Xue Za Zhi · journal article · DOI 10.7534/j.issn.1009-2137.2014.05.010

Bibliografisk träff 2014-06-01

[Effect of bromdomain protein 4 inhibitor GSK525762A on the proliferation and apoptosis of B-cell acute lymphoblastic leukemia cells and its mechanism].

Wang M, Chen C, Xu J, Wang L, Song X, Zhang H, Zeng L, Xu K.

Zhonghua Xue Ye Xue Za Zhi · research support, non-u.s. gov't; journal article · DOI 10.3760/cma.j.issn.0253-2727.2014.06.012